NasdaqGS:PCRX

Stock Analysis Report

Executive Summary

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Pacira BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.2%

PCRX

-1.2%

US Pharmaceuticals

0.07%

US Market


1 Year Return

-15.6%

PCRX

-6.3%

US Pharmaceuticals

8.9%

US Market

Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned -6.3% over the past year.

Return vs Market: PCRX underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

PCRXIndustryMarket
7 Day1.2%-1.2%0.07%
30 Day6.2%-1.9%-0.3%
90 Day-6.4%-2.0%-1.6%
1 Year-15.6%-15.6%-4.0%-6.3%11.3%8.9%
3 Year11.2%11.2%18.7%10.3%46.3%36.8%
5 Year-62.7%-62.7%21.6%8.8%62.1%44.3%

Price Volatility Vs. Market

How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCRX ($39.48) is trading below our estimate of fair value ($87.01)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCRX is poor value based on its PE Ratio (213.9x) compared to the Pharmaceuticals industry average (16.5x).

PE vs Market: PCRX is poor value based on its PE Ratio (213.9x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: PCRX is poor value based on its PEG Ratio (4.3x)


Price to Book Ratio

PB vs Industry: PCRX is overvalued based on its PB Ratio (4.8x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

49.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCRX's forecast earnings growth (49.7% per year) is above the savings rate (2.7%).

Earnings vs Market: PCRX's earnings (49.7% per year) are forecast to grow faster than the US market (14.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PCRX's revenue (10.9% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: PCRX's revenue (10.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PCRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pacira BioSciences performed over the past 5 years?

4.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 4.3% per year.

Accelerating Growth: PCRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PCRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: PCRX's Return on Equity (2.2%) is considered low.


Return on Assets

ROA vs Industry: PCRX's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: PCRX's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Pacira BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: PCRX's short term assets ($394.6M) exceeds its short term liabilities ($83.0M)

Long Term Liabilities: PCRX's short term assets (394.6M) exceeds its long term liabilities (363.2M)


Debt to Equity History and Analysis

Debt Level: PCRX's debt to equity ratio (87.3%) is considered high

Reducing Debt: PCRX's debt to equity ratio has increased from 68.8% to 87.3% over the past 5 years.

Debt Coverage: PCRX's debt is well covered by operating cash flow (21.5%).

Interest Coverage: PCRX's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet

Inventory Level: PCRX has a high level of physical assets or inventory.

Debt Coverage by Assets: PCRX's debt is covered by short term assets (assets are 1.323360x debt).


Next Steps

Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Pacira BioSciences's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Dave Stack (69yo)

11.9yrs

Tenure

US$5,835,918

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira Pharmaceutical ...


CEO Compensation Analysis

Compensation vs. Market: Dave's total compensation ($USD5.84M) is about average for companies of similar size in the US market ($USD4.07M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.4yrs

Average Tenure

53yo

Average Age

Experienced Management: PCRX's management team is considered experienced (3.4 years average tenure).


Board Age and Tenure

6.3yrs

Average Tenure

60yo

Average Age

Experienced Board: PCRX's board of directors are considered experienced (6.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$11,451,30206 Sep 19
Consonance Capital Management LP
EntityCompany
Shares264,119
Max PriceUS$43.36
SellUS$20,180,90405 Aug 19
Consonance Capital Management LP
EntityCompany
Shares449,827
Max PriceUS$44.86
SellUS$16,129,85810 Jul 19
Consonance Capital Management LP
EntityCompany
Shares361,656
Max PriceUS$44.60
SellUS$94,13912 Jun 19
Lauren Riker
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer & VP of Finance
Shares2,126
Max PriceUS$44.28
SellUS$30,98106 Jun 19
Roy Winston
EntityIndividual
Shares722
Max PriceUS$42.91
SellUS$108,51906 Jun 19
Kristen Dunker
EntityIndividual
Shares2,529
Max PriceUS$42.91
SellUS$531,44006 Jun 19
David Stack
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares12,385
Max PriceUS$42.91
SellUS$88,99506 Jun 19
Richard Scranton
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares2,074
Max PriceUS$42.91
SellUS$41,49406 Jun 19
Lauren Riker
EntityIndividual
Role
Chief Accounting Officer
Principal Accounting Officer & VP of Finance
Shares967
Max PriceUS$42.91
SellUS$47,45806 Jun 19
Charles Reinhart
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,106
Max PriceUS$42.91
SellUS$47,15806 Jun 19
Dennis McLoughlin
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,099
Max PriceUS$42.91
SellUS$18,45106 Jun 19
Charles Laranjeira
EntityIndividual
Role
Chief Technology Officer
Chief Technical Officer
Shares430
Max PriceUS$42.91
SellUS$20,377,74705 Jun 19
Consonance Capital Management LP
EntityCompany
Shares446,615
Max PriceUS$45.63
BuyUS$66,24408 Mar 19
Mark Kronenfeld
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,700
Max PriceUS$39.14
SellUS$680,49614 Dec 18
HBM Partners Ltd.
EntityCompany
Shares14,527
Max PriceUS$47.84
SellUS$46,60521 Nov 18
HBM Partners Ltd.
EntityCompany
Shares990
Max PriceUS$47.08
BuyUS$207,81021 Nov 18
Gary Pace
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares4,500
Max PriceUS$46.18
SellUS$3,337,58720 Nov 18
HBM Partners Ltd.
EntityCompany
Shares70,498
Max PriceUS$47.64
SellUS$272,98015 Nov 18
HBM Partners Ltd.
EntityCompany
Shares5,478
Max PriceUS$49.83
SellUS$2,977,09114 Nov 18
HBM Partners Ltd.
EntityCompany
Shares58,245
Max PriceUS$51.13
BuyUS$205,16009 Nov 18
Gary Pace
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares4,000
Max PriceUS$51.29

Ownership Breakdown


Management Team

  • Charlie Reinhart (58yo)

    Chief Financial Officer

    • Tenure: 3.4yrs
    • Compensation: US$1.41m
  • Dave Stack (69yo)

    Chairman & CEO

    • Tenure: 11.9yrs
    • Compensation: US$5.84m
  • Rich Scranton (52yo)

    Chief Medical Officer

    • Tenure: 1.2yrs
    • Compensation: US$2.27m
  • Charles Laranjeira (53yo)

    Chief Technical Officer

    • Tenure: 0.8yrs
  • Lauren Riker (40yo)

    Principal Accounting Officer & VP of Finance

    • Tenure: 7.6yrs
    • Compensation: US$288.82k
  • Max Reinhardt

    President

    • Tenure: 0.3yrs
  • Kristen Williams (45yo)

    Chief Administrative Officer & Secretary

    • Tenure: 5yrs
    • Compensation: US$1.94m
  • Richard Kahr

    Vice President of Human Resources

    • Tenure: 4.3yrs
  • Susan Mesco

    Head of Investor Relations

    • Tenure: 0yrs
  • Dennis McLoughlin (53yo)

    Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$2.53m

Board Members

  • Laura Brege (61yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$205.42k
  • Dave Stack (69yo)

    Chairman & CEO

    • Tenure: 11.9yrs
    • Compensation: US$5.84m
  • Paul Hastings (59yo)

    Lead Director

    • Tenure: 6.3yrs
    • Compensation: US$218.42k
  • Gary Pace (71yo)

    Independent Director

    • Tenure: 11.3yrs
    • Compensation: US$180.22k
  • Andreas Wicki (61yo)

    Independent Director

    • Tenure: 12.8yrs
  • John Longenecker (59yo)

    Independent Director

    • Tenure: 12.3yrs
    • Compensation: US$202.42k
  • Mark Kronenfeld (64yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$190.42k
  • Yvonne Greenstreet (56yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$184.42k
  • Chris Christie (56yo)

    Director

    • Tenure: 0.08yrs
  • Mark Froimson (58yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$175.42k

Company Information

Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: PCRX
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.644b
  • Shares outstanding: 41.64m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5 Sylvan Way
  • Suite 300
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2011
82PDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2011

Biography

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:17
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.